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Functional abdominal pain is pain located in the abdomen that cannot be explained by visible or detectable
abnormalties. It is hypothesised that the use of probiotics might alter the growth of bacteria in the bowel, promote
normal gut physiology and reduce functional symptoms. Given the recent growth in published studies in this area it is
necessary to produce a new and focussed synthesis of this evidence by deploying a robust methodology to ensure
that there can be a contemporaneous impact on clinical practice.
 
Methods
The Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, CINAHL and Cochrane Inflammatory Bowel
Disease & Functional Bowel Disorders Group Specialised Trial Register were searched (Inception – July 2015).
Manufacturers of probiotics were contacted to identify unpublished trials. References of trials were also searched.
Abstracts were considered for inclusion if full details to judge inclusion were offered or available from the authors.
Randomised controlled trials (RCTs) that compared probiotics against placebo or any other intervention were eligible
for inclusion. Data extraction and assessment of methodological quality of included studies were independently
performed by two authors. Analysis was completed in accordance with the intention to treat approach.
 
Results
The search yielded 1672 results and nine placebo controlled studies (n = 701) met the inclusion criteria, two as
abstracts and seven as published studies. Three studied Lactobacillus GG, three lactobacillus reuteri, one VSL#3, one
bacillus coagulans and one bifidobacteria. The studies ranged in length from 4 to 16 weeks. The risk of bias was low
for randomisation for seven trials and moderate for two trials. Allocation concealment was low in two studies and
unclear in the others. All studies were double blinded, but only four gave details of how this was achieved. The risk of
bias was low or unclear in all studies for incomplete outcome data and selective reporting. Meta-analysis of seven
studies (n=541) found a statistical significant reduction in the severity of pain using probiotics compared to placebo
(MD -0.32; 95% CI -0.38 to -0.25). Meta-analysis of four studies (n=440) found a statistical significant difference in
patients reaching treatment success favouring probiotics compared to placebo (OR 1.80; 95% CI 1.20 to 2.69). Meta-
analysis of five studies (n=385) found no statistical significant difference in adverse events between probiotics and
placebo (OR 0.00; 95% CI -0.07 to 0.06).
 
Conclusions
The evidence from the published suggests superior efficacy of probiotics for functional abdominal pain in children
when compared with placebo. There is no difference in adverse events, suggesting safety. The evidence base is of
moderate quality and relatively small. Further research to investigate the long term impact of probiotic therapy is
suggested.
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